Cover Image
市場調查報告書

轉移性胰臟癌:開發中產品分析

Metastatic Pancreatic Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229735
出版日期 內容資訊 英文 416 Pages
訂單完成後即時交付
價格
Back to Top
轉移性胰臟癌:開發中產品分析 Metastatic Pancreatic Cancer - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 416 Pages
簡介

會轉移到其他器官的胰臟癌就稱之為轉移性胰臟癌。必需使用化療等全身性治療才能破壞擴展到全身的癌細胞。主要的症狀有上腹部痛、皮膚變黃、眼白發黃(黃疸症狀)、食慾不振、體重減少、憂鬱症、血栓等。治療方法包含外科手術,放射線治療,化療等。

本報告提供轉移性胰臟癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

轉移性胰臟癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

轉移性胰臟癌:企業開發中的治療藥

轉移性胰臟癌:大學/機關研究中的治療藥

轉移性胰臟癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

轉移性胰臟癌:企業開發中的產品

轉移性胰臟癌:大學/機關研究中的產品

轉移性胰臟癌的治療藥的開發企業

  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • ArQule, Inc.
  • Array BioPharma Inc.
  • AstraZeneca Plc
  • Axcentua Pharmaceuticals AB
  • Berg LLC
  • Bionomics Limited
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Clovis Oncology, Inc.
  • Cornerstone Pharmaceuticals, Inc.
  • CTI BioPharma Corp.
  • CytRx Corporation
  • Eleison Pharmaceuticals LLC
  • Eli Lilly and Company
  • Ensol Biosciences Inc.
  • Erytech Pharma SA
  • F. Hoffmann-La Roche Ltd.
  • Fountain Biopharma Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • HanAll Biopharma Co., Ltd.
  • Immodulon Therapeutics Ltd.
  • Incyte Corporation
  • MabVax Therapeutics Holdings, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Momenta Pharmaceuticals, Inc.
  • NanoCarrier Co., Ltd.
  • NantKwest, Inc.
  • Natco Pharma Limited
  • NewLink Genetics Corporation
  • Novartis AG
  • Oncolytics Biotech Inc.
  • Oncovir, Inc.
  • Oryx GmbH & Co. KG
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Pharmacyclics, Inc.
  • Phoenix Biotechnology, Inc.
  • Plexxikon Inc.
  • Precision Biologics, Inc.
  • Redx Pharma Plc
  • Rexahn Pharmaceuticals, Inc.
  • Sanofi
  • Silence Therapeutics Plc
  • Targovax AS
  • Zeria Pharmaceutical Co., Ltd.

轉移性胰臟癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

轉移性胰臟癌:最近的開發平台趨勢

轉移性胰臟癌:暫停中的計劃

轉移性胰臟癌:暫停中的計劃

轉移性胰臟癌:開發中止的產品

轉移性胰臟癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8466IDB

Summary

Global Markets Direct's, 'Metastatic Pancreatic Cancer - Pipeline Review, H2 2016', provides an overview of the Metastatic Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
  • The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Pancreatic Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Pancreatic Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Pancreatic Cancer - Overview
    • Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis
  • Metastatic Pancreatic Cancer - Therapeutics under Development by Companies
  • Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Pancreatic Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Pancreatic Cancer - Products under Development by Companies
  • Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Aduro BioTech, Inc.
    • ArQule, Inc.
    • Array BioPharma Inc.
    • AstraZeneca Plc
    • Axcentua Pharmaceuticals AB
    • Berg LLC
    • BioLineRx, Ltd.
    • Bionomics Limited
    • Boehringer Ingelheim GmbH
    • Boston Biomedical, Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Clovis Oncology, Inc.
    • Cornerstone Pharmaceuticals, Inc.
    • CrystalGenomics, Inc.
    • CTI BioPharma Corp.
    • CytRx Corporation
    • Daiichi Sankyo Company, Limited
    • Eleison Pharmaceuticals LLC
    • Eli Lilly and Company
    • Ensol Biosciences Inc.
    • Erytech Pharma SA
    • F. Hoffmann-La Roche Ltd.
    • Fountain Biopharma Inc.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Immodulon Therapeutics Ltd.
    • Incyte Corporation
    • MabVax Therapeutics Holdings, Inc.
    • Merck & Co., Inc.
    • Merrimack Pharmaceuticals, Inc.
    • NanoCarrier Co., Ltd.
    • NantKwest, Inc.
    • Natco Pharma Limited
    • NewLink Genetics Corporation
    • Novartis AG
    • Oncolytics Biotech Inc.
    • Oncovir, Inc.
    • Oryx GmbH & Co. KG
    • Pfizer Inc.
    • Pharmacyclics, Inc.
    • Phoenix Biotechnology, Inc.
    • Precision Biologics, Inc.
    • Rexahn Pharmaceuticals, Inc.
    • Silence Therapeutics Plc
    • Targovax ASA
    • Tiltan Pharma Ltd.
    • Tocagen Inc.
    • Zeria Pharmaceutical Co., Ltd.
  • Metastatic Pancreatic Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile
    • 5B1-ADC - Drug Profile
    • acalabrutinib - Drug Profile
    • aldoxorubicin hydrochloride - Drug Profile
    • alpelisib - Drug Profile
    • ARQ-761 - Drug Profile
    • asparaginase - Drug Profile
    • atezolizumab - Drug Profile
    • Atu-027 - Drug Profile
    • avasimibe - Drug Profile
    • AXP-10711 - Drug Profile
    • BI-853520 - Drug Profile
    • binimetinib - Drug Profile
    • BL-8040 - Drug Profile
    • BNC-101 - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile
    • ceritinib - Drug Profile
    • CG-200745 - Drug Profile
    • Charis-1000 - Drug Profile
    • CIM-1 - Drug Profile
    • cisplatin - Drug Profile
    • CPI-613 - Drug Profile
    • dacomitinib - Drug Profile
    • ensituximab - Drug Profile
    • FB-704A - Drug Profile
    • flucytosine ER + vocimagene amiretrorepvec - Drug Profile
    • galunisertib - Drug Profile
    • glufosfamide - Drug Profile
    • GS-5745 - Drug Profile
    • GSK-2256098 - Drug Profile
    • haNK Program - Drug Profile
    • HuMab-5B1 - Drug Profile
    • ibrutinib - Drug Profile
    • IMM-101 - Drug Profile
    • INCB-52793 - Drug Profile
    • indoximod - Drug Profile
    • irinotecan hydrochloride - Drug Profile
    • istiratumab - Drug Profile
    • lapatinib ditosylate - Drug Profile
    • LCL-161 - Drug Profile
    • MesoCART - Drug Profile
    • MK-2206 - Drug Profile
    • MK-2206 + selumetinib sulfate - Drug Profile
    • Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
    • MVT-1075 - Drug Profile
    • napabucasin - Drug Profile
    • nimotuzumab - Drug Profile
    • NRCAN-019 - Drug Profile
    • olaparib - Drug Profile
    • paclitaxel albumin bound - Drug Profile
    • palbociclib - Drug Profile
    • Parvoryx - Drug Profile
    • PBI-05204 - Drug Profile
    • PCI-27483 - Drug Profile
    • pelareorep - Drug Profile
    • PLX-7486 - Drug Profile
    • Poly-ICLC - Drug Profile
    • PRI-724 - Drug Profile
    • RG-7876 - Drug Profile
    • ribociclib succinate - Drug Profile
    • rottlerin - Drug Profile
    • rucaparib camsylate - Drug Profile
    • RX-0201 - Drug Profile
    • SGT-53 - Drug Profile
    • Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile
    • sonidegib phosphate - Drug Profile
    • TG-01 - Drug Profile
    • TL-118 - Drug Profile
    • tosedostat - Drug Profile
    • trametinib dimethyl sulfoxide - Drug Profile
    • ubidecarenone - Drug Profile
    • ulixertinib - Drug Profile
    • ulocuplumab - Drug Profile
    • Vaccine for Oncology - Drug Profile
    • veliparib - Drug Profile
    • Z-360 - Drug Profile
  • Metastatic Pancreatic Cancer - Dormant Projects
  • Metastatic Pancreatic Cancer - Discontinued Products
  • Metastatic Pancreatic Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016
  • Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by ArQule, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Array BioPharma Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Berg LLC, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by BioLineRx, Ltd., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Bionomics Limited, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by CytRx Corporation, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Merck & Co., Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by NantKwest, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Natco Pharma Limited, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics Plc, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Targovax ASA, H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Tiltan Pharma Ltd., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Tocagen Inc., H2 2016
  • Metastatic Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Pancreatic Cancer - Dormant Projects, H2 2016
  • Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H2 2016
  • Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H2 2016
  • Metastatic Pancreatic Cancer - Dormant Projects (Contd..3), H2 2016
  • Metastatic Pancreatic Cancer - Dormant Projects (Contd..4), H2 2016
  • Metastatic Pancreatic Cancer - Discontinued Products, H2 2016
  • Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H2 2016
  • Metastatic Pancreatic Cancer - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016
  • Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top